A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case Study

Low calorie liquid meal replacements can be used to achieve weight loss in obese patients. Many consider renal disease a contraindication to this due to a lack of specific research. The aim of this case study is to illustrate that this therapy can be used effectively in Chronic Kidney Disease (CKD)....

Full description

Bibliographic Details
Main Authors: Belinda Morey, Jillian Murray
Format: Article
Language:English
Published: The Korean Society of Nephrology 2012-06-01
Series:Kidney Research and Clinical Practice
Online Access:http://www.sciencedirect.com/science/article/pii/S221191321200527X
id doaj-d2c217f2e3c147e5911e877b56afa1aa
record_format Article
spelling doaj-d2c217f2e3c147e5911e877b56afa1aa2020-11-24T21:08:05ZengThe Korean Society of NephrologyKidney Research and Clinical Practice2211-91322012-06-01312A5910.1016/j.krcp.2012.04.494A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case StudyBelinda MoreyJillian MurrayLow calorie liquid meal replacements can be used to achieve weight loss in obese patients. Many consider renal disease a contraindication to this due to a lack of specific research. The aim of this case study is to illustrate that this therapy can be used effectively in Chronic Kidney Disease (CKD). After numerous failed weight loss attempts, the multidisciplinary team (Nephrology, Endocrinology, General Practice and Dietetics) decided to trial a 65 year old patient (CKD Stage 3 secondary to Type 2 Diabetes Mellitus requiring insulin) on a modified meal replacement plan. This plan consisted of 3 Optifast meal replacement drinks plus one portion controlled meal, (4MJ and 85g of protein per day). Monitoring included frequent blood glucose self testing, fortnightly blood tests and review by the Dietitian (monthly once stable). The patient was initially unable to exercise due to pain. At baseline, weight was 157 kg (BMI: 41 kg/m2), waist circumference 155cm and blood biochemistry indicated CKD stage 3b (eGFR: 39 ml/min, Urea: 15.9 mmol/L, Creat: 156 umol/L). After 14 weeks weight had decreased 22 kg (BMI: 35.8 kg/m2), waist circumference had decreased 18 cm and reported pain improved. Insulin requirements approximately halved, and blood biochemistry (eGFR: 42 ml/min, Urea: 15.2 mmol/L, Creat: 147 umol/L) indicated no decline in renal function. With close monitoring a modified meal replacement plan was used successfully in a patient with CKD however prospective randomised trials are required to further investigate this treatment.http://www.sciencedirect.com/science/article/pii/S221191321200527X
collection DOAJ
language English
format Article
sources DOAJ
author Belinda Morey
Jillian Murray
spellingShingle Belinda Morey
Jillian Murray
A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case Study
Kidney Research and Clinical Practice
author_facet Belinda Morey
Jillian Murray
author_sort Belinda Morey
title A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case Study
title_short A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case Study
title_full A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case Study
title_fullStr A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case Study
title_full_unstemmed A Modified Meal Replacement Plan As Weight Loss Treatment In Chronic Kidney Disease: A Case Study
title_sort modified meal replacement plan as weight loss treatment in chronic kidney disease: a case study
publisher The Korean Society of Nephrology
series Kidney Research and Clinical Practice
issn 2211-9132
publishDate 2012-06-01
description Low calorie liquid meal replacements can be used to achieve weight loss in obese patients. Many consider renal disease a contraindication to this due to a lack of specific research. The aim of this case study is to illustrate that this therapy can be used effectively in Chronic Kidney Disease (CKD). After numerous failed weight loss attempts, the multidisciplinary team (Nephrology, Endocrinology, General Practice and Dietetics) decided to trial a 65 year old patient (CKD Stage 3 secondary to Type 2 Diabetes Mellitus requiring insulin) on a modified meal replacement plan. This plan consisted of 3 Optifast meal replacement drinks plus one portion controlled meal, (4MJ and 85g of protein per day). Monitoring included frequent blood glucose self testing, fortnightly blood tests and review by the Dietitian (monthly once stable). The patient was initially unable to exercise due to pain. At baseline, weight was 157 kg (BMI: 41 kg/m2), waist circumference 155cm and blood biochemistry indicated CKD stage 3b (eGFR: 39 ml/min, Urea: 15.9 mmol/L, Creat: 156 umol/L). After 14 weeks weight had decreased 22 kg (BMI: 35.8 kg/m2), waist circumference had decreased 18 cm and reported pain improved. Insulin requirements approximately halved, and blood biochemistry (eGFR: 42 ml/min, Urea: 15.2 mmol/L, Creat: 147 umol/L) indicated no decline in renal function. With close monitoring a modified meal replacement plan was used successfully in a patient with CKD however prospective randomised trials are required to further investigate this treatment.
url http://www.sciencedirect.com/science/article/pii/S221191321200527X
work_keys_str_mv AT belindamorey amodifiedmealreplacementplanasweightlosstreatmentinchronickidneydiseaseacasestudy
AT jillianmurray amodifiedmealreplacementplanasweightlosstreatmentinchronickidneydiseaseacasestudy
AT belindamorey modifiedmealreplacementplanasweightlosstreatmentinchronickidneydiseaseacasestudy
AT jillianmurray modifiedmealreplacementplanasweightlosstreatmentinchronickidneydiseaseacasestudy
_version_ 1716760901817729024